ArticleBiosensors & bioelectronics2022
An all-in-one point-of-care testing device for multiplexed detection of respiratory infections.
Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Biosensors as transformative tools for multiplex detection of respiratory viral pathogens.Archives of microbiology · 2026Review
- Intelligent microfluidic device for multiplex detection and prompt warning of upper and lower respiratory tract infections.Journal of advanced research · 2026Article
- WoundMx: multiplexed detection of wound infection biomarkers with a multimodal sensor system based on laser-induced graphene.NPJ 2D materials and applications · 2026Article
- Smartphone-driven centrifugal microfluidics for diagnostics in resource limited settings.Biomedical microdevices · 2024Article
- Article
- Influenza viruses and SARS-CoV-2 diagnosis via sensitive testing methods in clinical application.Heliyon · 2024Review
- Advancing Microfluidic Immunity Testing Systems: New Trends for Microbial Pathogen Detection.Molecules (Basel, Switzerland) · 2024Review
- A Highly Sensitive Dual-Drive Microfluidic Device for Multiplexed Detection of Respiratory Virus Antigens.Micromachines · 2024Article
- Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study.Materials today. Bio · 2024Review
- Trends of respiratory virus detection in point-of-care testing: A review.Analytica chimica acta · 2023Review
- Newly Developed Electrochemiluminescence Based on Bipolar Electrochemistry for Multiplex Biosensing Applications: A Consolidated Review.Biosensors · 2023Review
- Review
- Challenges and perspectives of multi-virus biosensing techniques: A review.Analytica chimica acta · 2023Review
- Application of microfluidic technologies on COVID-19 diagnosis and drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- Patterned Biolayers of Protein Antigens for Label-Free Biosensing in Cow Milk Allergy.Biosensors · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of the COVID-19 pandemic has reinforced the need for rapid, cost-effective, and reliable point-of-care testing (POCT) devices for massive population screening. The co-circulation of SARS-CoV-2 with several seasonal respiratory viruses highlights the need for multiplexed biosensing approaches. Herein, we present a fast and robust all-in-one POCT device for parallel viral antigen and serological analysis. The biosensing approach consists of a functionalized polycarbonate disc-shaped surface with microfluidic structures, where specific bioreagents are immobilized in microarray format, and a portable optoelectronic analyzer. The biosensor quantifies the concentration of viral antigens and specific immunoglobulins G and M for SARS-CoV-2, influenza A/B, adenovirus, and respiratory syncytial virus, using 30 μL of a sample. The semi-automated analysis of 6 samples is performed in 30 min. Validation studies performed with 135 serum samples and 147 nasopharyngeal specimens reveal high diagnostic sensitivity (98-100%) and specificity (84-98%), achieving an excellent agreement (κ = 0.937) with commercial immunoassays, which complies with the World Health Organization criteria for POC COVID-19 diagnostic tests. The versatility of the POCT device paves the way for the detection of other pathogens and analytes in the incoming post-pandemic world, integrating specific bioreagents against different variants of concerns and interests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.